CURRENT VIEWS OF A DIFFERENTIATED APPROACH TO CHOOSING A SUPEROVULATION STIMULATION PROTOCOL IN IVF CYCLES


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Objective. To summarize available data on different superovulation stimulation protocols in assisted reproductive technology programs, on their currently available modifications, and on indications for their use. Material and methods. Respective sources were sought for in the systems Medline, Cochrane Library, and Elibrary; these included publications from January 2005 to October 2015. Thirty of the found 807 investigations were used to write a systematic review. Results. Today there are different controlled ovarian stimulation (COS) protocols; but the most common protocols among them in clinical practice are a “long” protocol with gonadotropin-releasing hormone agonists, a protocol with gonadotropin-releasing hormone antagonists, and its different modifications. Meticulous attention is given to the elaboration of regimens for the replacement of an ovulation trigger as a method to prevent ovarian hyperstimulation syndrome. The choice of a superovulation stimulation regimen should be individual and depend on many factors. Conclusion. Today there is a rich variety of modified COS protocols; experience has been accumulated regarding some indications for the use of one or other stimulation protocol in relation to the clinic-anamnestic and embryologic characteristics of patients; however, contradictory and ambiguous data on their efficiency call for further investigations in this area.

全文:

受限制的访问

作者简介

Anastasia Syrkasheva

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: anast.syrkasheva@gmail.com
MD, Researcher of R&D Department 17997, Russia, Moscow, Ac. Oparina str. 4

Margarita Agarsheva

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia

Email: agarsheva.m@gmail.com
undergraduate Moscow 117997, Ac. Oparina str. 4, Russia

Maria Andreeva

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: onischenkomaria@mail.ru
MD, Postgraduate of the Department of assistive reproductive technology in the treatment of infertility 17997, Russia, Moscow, Ac. Oparina str. 4

Nataliya Dolgushina

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: n_dolgushina@oparina4.ru
M.D., Ph.D., M.P.H., Head of R&D Department 17997, Russia, Moscow, Ac. Oparina str. 4

Elena Kalinina

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: e_kalinina@oparina4.ru
M.D., Ph.D., Head of the Department of assistive reproductive technology in the treatment of infertility 17997, Russia, Moscow, Ac. Oparina str. 4

Ekaterina Yarotskaya

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: e_yarotskaya@oparina4.ru
M.D., Ph.D., Head of the Department for International Cooperation 17997, Russia, Moscow, Ac. Oparina str. 4

参考

  1. Fauser B.C.J.M., Diedrich K., Devroey P.; Evian Annual Reproduction Workshop Group 2007. Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation. Hum. Reprod. Update. 2008; 14(1): 1-14.
  2. Nardo L.G., Fleming R., Howles C.M., Bosch E., Hamamah S., Ubaldi F.M. et al. Conventional ovarian stimulation no longer exists: welcome to the age of individualized ovarian stimulation. Reprod. Biomed. Online. 2011; 23(2): 141-8.
  3. Orvieto R., Homburg R., Meltcer S., Rabinson J., Anteby E.Y., Scharf S. GnRH agonist versus GnRH antagonist in controlled ovarian hyperstimulation: their role in patients with an unfavorable prognosis a priori. Fertil. Steril. 2009; 91(4, Suppl.): 1378-80.
  4. Reh A., Krey L., Noyes N. Are gonadotropin-releasing hormone agonists losing popularity? Current trends at a large fertility center. Fertil. Steril. 2010; 93(1): 101-8.
  5. Al-Inany H.G., Youssef M.A., Aboulghar M., Broekmans F., Sterrenburg M., Smit J. et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst. Rev. 2011; (5): CD001750.
  6. Xiao J., Su C., Zeng X. Comparisons of GnRH antagonist versus GnRH agonist protocol in supposed normal ovarian responders undergoing IVF: a systematic review and meta-analysis. PLoS One. 2014; 9(9): e106854.
  7. Al-Inany H., Aboulghar M. GnRH antagonist in assisted reproduction: a Cochrane review. Hum. Reprod. 2002; 17(4): 874-85.
  8. Pundir J., Sunkara S.K., El-Toukhy T., Khalaf Y. Meta-analysis of GnRH antagonist protocols: do they reduce the risk of OHSS in PCOS? Reprod. Biomed. Online. 2012; 24(1): 6-22.
  9. Al-Inany H.G., Abou-Setta A.M., Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review. Reprod. Biomed. Online. 2007; 14(5): 640-9.
  10. Nargund G., Fauser B.C.J.M., Macklon N.S., Ombelet W., Nygren K., Frydman R. The ISMAAR proposal on terminology for ovarian stimulation for IVF. Hum. Reprod. 2007; 22(11): 2801-4.
  11. Калинина Е.А., Березикова М.В., Бурменская О.В., Подрез Л.А. Применение «мягкого» протокола стимуляции суперовуляции в программах вспомогательных репродуктивных технологий: эффективность и безопасность. Акушерство и гинекология. 2012; 4-2: 51-6.
  12. Stimpfel M., Vrtacnik-Bokal E., Pozlep B., Virant-Klun I. Comparison of GnRH agonist, GnRH antagonist, and GnRH antagonist mild protocol of controlled ovarian hyperstimulation in good prognosis patients. Int. J. Endocrinol. 2015; 2015: 385049.
  13. Калинина Е. А., Эбзеева М. В., Кузьмичев Л. Н. Опыт применения «мягких» схем стимуляции суперовуляции у пациенток группы риска развития синдрома гиперстимуляции яичников. Акушерство и гинекология. 2010; 6: 60-4.
  14. Griesinger G., Venetis C.A., Marx T., Diedrich K., Tarlatzis B.C., Kolibianakis E.M. Oral contraceptive pill pretreatment in ovarian stimulation with GnRH antagonists for IVF: a systematic review and meta-analysis. Fertil. Steril. 2008; 90(4): 1055-63.
  15. Griesinger G., Kolibianakis E.M., Venetis C., Diedrich K., Tarlatzis B. Oral contraceptive pretreatment significantly reduces ongoing pregnancy likelihood in gonadotropin-releasing hormone antagonist cycles: an updated meta-analysis. Fertil. Steril. 2010; 94(6): 2382-4.
  16. Blocked C., Baumgarten M., De Vos M., Verheyen G., Devroey P. Administration of GnRH antagonists in case of elevated progesterone at initiation of the cycle: a prospective cohort study. Curr. Pharm. Biotech. 2010; 12(3): 423-8.
  17. Blockeel C., Riva A., De Vos M., Haentjens P., Devroey P. Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm injection treatment cycle: impact on ovarian stimulation. A pilot study. Fertil. Steril. 2011; 95(5): 1714-9.
  18. Cakmak H., Tran N., Zamah M., Cedars M., Rosen M. A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders.Fertil. Seril. 2014; 101(5): 1308-14.
  19. Choi J., Smitz J. Luteinizing hormone and human chorionic gonadotropin: origins of difference. Mol. Cell. Endocrinol. 2014; 383(1-2): 203-13.
  20. Tobler K.J., Zhao Y., Weissman A., Majumdar A., Leong M., Shoham Z. Worldwide survey of IVF practices: trigger, retrieval and embryo transfer techniques. Arch. Gynecol. Obstet. 2014; 290(3): 561-8.
  21. Humaidan P., Papanikolaou E.G., Tarlatzis B.C. Reply: GnRHa to trigger final oocyte maturation: a time to reconsider. Hum. Reprod. 2010; 25(3): 807-8.
  22. Griesinger G., Kolibianakis E.M., Papanikolaou E.G., Diedrich K., Van Steirteghem A., Devroey P. et al. Triggering of final oocyte maturation with gonadotropin-releasing hormone agonist or human chorionic gonadotropin. Live birth after frozen-thawed embryo replacement cycles. Fertil. Steril. 2007; 88(3): 616-21.
  23. Мартазанова Б.А., Мишиева Н.Г., Ведихина И.А., Аксененко А.А., Ипен С.М., Ибрагимова М.Х., Иванец Т.Ю., Абубакиров А.Н. Гормональный профиль после замены триггера овуляции у женщин с высоким риском развития синдрома гиперстимуляции яичников. Акушерство и гинекология. 2015; 6: 84-90.
  24. Youssef M.A.F.M., Van der Veen F., Al-Inany H.G., Mochtar M.H., Griesinger G., Nagi Mohesen M. et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst. Rev. 2014; (10): CD008046.
  25. Kuang Y., Chen Q., Hong Q., Lyu Q., Ai A., Fu Y. et al. Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (Shanghai protocol). Reprod. Biomed. Online. 2014; 29(6): 684-91.
  26. Виноградова Л.В., Мишиева Н.Г., Абубакиров А.Н., Левков Л.А., Мартынова М.В. Гормональные особенности циклов ЭКО, стимулированных человеческим менопаузальным гонадотропином и рекомбинатным ФСГ в протоколах с антагонистом гонадотропин-рилизинг гормона. Акушерство и гинекология. 2014; 11: 88-95.
  27. Митюрина Е.В., Перминова С.Г., Демура Т.А., Галлямова Е.В. Морфофункциональное состояние эндометрия в стимулированных циклах программы экстракорпорального оплодотворения. Акушерство и гинекология. 2014; 11: 80-7.
  28. Gianaroli L., Magli M.C., Ferraretti A.P., Fiorentino A., Garrisi J., Munné S. Preimplantation genetic diagnosis increases the implantation rate in human in vitro fertilization by avoiding the transfer of chromosomally abnormal embryos. Fertil. Steril. 1997; 68(6): 1128-31.
  29. Yoldemir T. Does the duration of gonadotropin stimulation affect embryo quality on post-retrieval day 3? Gynecol. Endocrinol. 2011; 27(5): 324-30.
  30. Clément P. Consequences of stimulation on oocyte quality. Gynecol. Obstet. Fertil. 2007; 35(9): 890-7.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2016
##common.cookie##